NEW DELHI, March 5 (Reuters) - India's Ranbaxy Laboratories RANB.BO said on Thursday it had received the U.S. Food and Drug Administration's approval to make and sell blood pressure drug Quinaprilt Hydrochloride and Hydrochlorothiazide, a bioequivalent of Pfizer's PFE.N Accuretic tablets.
Ranbaxy said in a statement it had got approvals for the 10/12.5 mg, 20/12.5 mg and 20/25 mg versions of the drug.
It said the application had been submitted from its OHM Laboratories facility in New Jersey. (Reporting by Devidutta Tripathy, Editing by Mark Williams
Our Standards: The Thomson Reuters Trust Principles.